Market Research

Drug Repurposing Market (Disease Indication: Oncology, CNS Diseases, Neurodegenerative Diseases, and Others; and End-user: Hospitals & Clinics, Ambulatory Surgery Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast,

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 134 Pages Transparency Market Research Pvt. Ltd. June, 2024 TNPR19060455
Best Price Guarantee
Price from $5,795
Length 134 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date June, 2024
SKU TNPR19060455

Drug Repurposing Market (Disease Indication: Oncology, CNS Diseases, Neurodegenerative Diseases, and Others; and End-user: Hospitals & Clinics, Ambulatory Surgery Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034


Drug Repurposing Market – Scope of Report

TMR’s report on the global drug repurposing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global drug repurposing market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global drug repurposing market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the drug repurposing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global drug repurposing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global drug repurposing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global drug repurposing market.

The report delves into the competitive landscape of the global drug repurposing market. Key players operating in the global drug repurposing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global drug repurposing market profiled in this report.

Key Questions Answered in Global drug repurposing Market Report
  • What is the sales/revenue generated by drug repurposing across all regions during the forecast period?
  • What are the opportunities in the global drug repurposing market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Drug Repurposing Market – Research Objectives and Research Approach

The comprehensive report on the global drug repurposing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global drug repurposing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global drug repurposing market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Drug Repurposing Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Drug Repurposing Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Drug Repurposing Market Analysis and Forecast, by Disease Indication
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Indication, 2020-2034
6.3.1. Oncology
6.3.2. CNS Diseases
6.3.3. Neurodegenerative Diseases
6.3.4. Others (Rare Disorders, etc.)
6.4. Market Attractiveness Analysis, by Disease Indication
7. Global Drug Repurposing Market Analysis and Forecast, by Approach Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Approach Type, 2020-2034
7.3.1. Disease-centric approach
7.3.2. Target-centric approach
7.3.3. Drug-centric approach
7.4. Market Attractiveness Analysis, by Approach Type
8. Global Drug Repurposing Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Hospitals & Clinics
8.3.2. Ambulatory Surgery Diseases
8.3.3. Others (Research Institutes, etc.)
8.4. Market Attractiveness Analysis, by End-user
9. Global Drug Repurposing Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Drug Repurposing Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Disease Indication, 2020-2034
10.3.1. Oncology
10.3.2. CNS Diseases
10.3.3. Neurodegenerative Diseases
10.3.4. Others (Rare Disorders, etc.)
10.4. Market Value Forecast, by Approach Type, 2020-2034
10.4.1. Disease-centric approach
10.4.2. Target-centric approach
10.4.3. Drug-centric approach
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Hospitals & Clinics
10.5.2. Ambulatory Surgery Diseases
10.5.3. Others (Research Institutes, etc.)
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Disease Indication
10.7.2. By Approach Type
10.7.3. By End-user
10.7.4. By Country
11. Europe Drug Repurposing Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Disease Indication, 2020-2034
11.3.1. Oncology
11.3.2. CNS Diseases
11.3.3. Neurodegenerative Diseases
11.3.4. Others (Rare Disorders, etc.)
11.4. Market Value Forecast, by Approach Type, 2020-2034
11.4.1. Disease-centric approach
11.4.2. Target-centric approach
11.4.3. Drug-centric approach
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Hospitals & Clinics
11.5.2. Ambulatory Surgery Diseases
11.5.3. Others (Research Institutes, etc.)
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Disease Indication
11.7.2. By Approach Type
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Drug Repurposing Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Disease Indication, 2020-2034
12.3.1. Oncology
12.3.2. CNS Diseases
12.3.3. Neurodegenerative Diseases
12.3.4. Others (Rare Disorders, etc.)
12.4. Market Value Forecast, by Approach Type, 2020-2034
12.4.1. Disease-centric approach
12.4.2. Target-centric approach
12.4.3. Drug-centric approach
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Hospitals & Clinics
12.5.2. Ambulatory Surgery Diseases
12.5.3. Others (Research Institutes, etc.)
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Disease Indication
12.7.2. By Approach Type
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Drug Repurposing Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Disease Indication, 2020-2034
13.3.1. Oncology
13.3.2. CNS Diseases
13.3.3. Neurodegenerative Diseases
13.3.4. Others (Rare Disorders, etc.)
13.4. Market Value Forecast, by Approach Type, 2020-2034
13.4.1. Disease-centric approach
13.4.2. Target-centric approach
13.4.3. Drug-centric approach
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Hospitals & Clinics
13.5.2. Ambulatory Surgery Diseases
13.5.3. Others (Research Institutes, etc.)
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Disease Indication
13.7.2. By Approach Type
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Drug Repurposing Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Disease Indication, 2020-2034
14.3.1. Oncology
14.3.2. CNS Diseases
14.3.3. Neurodegenerative Diseases
14.3.4. Others (Rare Disorders, etc.)
14.4. Market Value Forecast, by Approach Type, 2020-2034
14.4.1. Disease-centric approach
14.4.2. Target-centric approach
14.4.3. Drug-centric approach
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Hospitals & Clinics
14.5.2. Ambulatory Surgery Diseases
14.5.3. Others (Research Institutes, etc.)
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Disease Indication
14.7.2. By Approach Type
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Algernon Pharmaceuticals
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Biovista Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Celentyx Ltd.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. ChemBio Discovery Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Chord Therapeutics SA
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Excelra
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Fios Genomics Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Lantern Pharma Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Novartis AG
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Paradigm Biopharmaceuticals Limited
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Predictive Oncology
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Segue Therapeutics, LLC
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Teva Pharmaceutical Industries Ltd.
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings